An additional example of success in combining CHK1 inhibitors with inhibitors of targets involved in the pro-survival pathway in melanoma was given by the observed synergistic effect in combining the AXL inhibitor BGB324 with the CHK1 inhibitor AZD-7762 [72]. Here, AXL is linked to melanoma.